Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-30T05:01:25.010Z Has data issue: false hasContentIssue false
  • English
  • Français

Isoniazid-Resistant Cavitary Tuberculosis in a Physician Following Isoniazid Prophylaxis

Published online by Cambridge University Press:  02 January 2015

Tobi B. Karchmer ,
John D. Phipps ,
Eve T. Giannetta  and
Barry M. Farr
Tobi B. Karchmer
Affiliation:
University of Virginia Health System, Charlottesville, Virginia
John D. Phipps
Affiliation:
University of Virginia Health System, Charlottesville, Virginia
Eve T. Giannetta
Affiliation:
University of Virginia Health System, Charlottesville, Virginia
Barry M. Farr*
Affiliation:
University of Virginia Health System, Charlottesville, Virginia
*
Box 473, University of Virginia Health System, Charlottesville, VA 22908
Get access Rights & Permissions [Opens in a new window]

Abstract

Single-drug prophylaxis is recommended after tuberculin skin test conversion, but not when there is active disease on chest radiograph because resistance develops frequently. Isoniazid-resistant tuberculosis developed in a physician receiving prophylaxis despite “faint left upper lobe soft tissue density” on chest radiograph. Ignoring active disease on chest x-ray renders this strategy counterproductive and cost ineffective. '(Infect Control Hosp Epidemiol 2002;23:622-625).

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 23 , Issue 10 , October 2002 , pp. 622 - 625
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Sudre, P, ten Dam, G, Kochi, A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992;70:149–159.Google ScholarPubMed
2.Riley, LW. Drug-resistant tuberculosis. Clin Infect Dis 1993;17(suppl 2):S442–S446.CrossRefGoogle ScholarPubMed
3.Fischl, MA, Daikos, GL, Uttamchandani, RB, et alClinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992;117:184–190.CrossRefGoogle ScholarPubMed
4.Goble, M, Iseman, MD, Madsen, LA, Waite, D, Ackerson, L, Horsburgh, CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527–532.Google Scholar
5.Frieden, TR, Sterling, T, Pablos-Mendez, A, Kilburn, JO, Cauthen, GM, Dooley, SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521–526.Google Scholar
6.Marshall, G, Crofton, JW, Cruickshank, R, et alThe treatment of pulmonary tuberculosis with isoniazid. BMJ 1952;2:735–746.Google Scholar
7.Alford, RH, Wallace, RJ. Antimycobacterial agents. In: Mandell, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases, 4th ed. New York: Churchill Livingstone; 1995:389–400.Google Scholar